Stocks Health care VRDN
NASDAQ · Health careViridian Therapeutics, Inc. (VRDN)
Viridian Therapeutics, Inc. brought in $71.1M of revenue over the twelve months to June 30, 2026, up 23,220.3% from a year earlier. It posted a net loss of $387M. In fiscal 2025 capital spending exceeded operating cash flow by $276.9M. At June 30, 2026 it held $165M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Viridian Therapeutics, Inc. does
Viridian Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VRDN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $70.8M | -$342.6M | n/a | -$276.9M |
| 2024 | $302K | -$269.9M | n/a | -$232.8M |
| 2023 | $314K | -$237.7M | -$5.31 | -$185.1M |
| 2022 | $1.8M | -$129.9M | -$4.05 | -$94.6M |
| 2021 | $3M | -$79.4M | -$6.66 | -$54.9M |
| 2020 | $1.1M | -$110.7M | -$31.13 | -$29.8M |
Latest SEC filings
What Viridian Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 20, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- June 29, 2026
- June 26, 2026Passive stake (5% or more) SCHEDULE 13G
- June 3, 2026
Questions about VRDN
What does Viridian Therapeutics, Inc. do?
Viridian Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker VRDN.
Is Viridian Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $387M on revenue of $71.1M.
How much revenue does Viridian Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Viridian Therapeutics, Inc. reported revenue of $71.1M. That is 23,220.3% more than a year earlier.
When did Viridian Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 20, 2026.
Similar companies
Follow VRDN
Get an email when Viridian Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VRDN: get an email when it filesWhere the numbers come from
Financial figures are the values Viridian Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.